Biocon gets FDA approval to produce pegfilgrastim in India

Biocon Biologics has won FDA approval of to begin producing the blood cell booster Fulphila for Mylan at its Bengaluru facility in India. (Biocon)

Biocon Biologics has won FDA approval of a supplemental Biologics License Application to begin producing Fulphila (pegfilgrastim) for Mylan at its Bengaluru facility in India.

The drug is a blood cell booster used to treat cancer patients by helping decrease the incidence of infection in cancer patients with non-myeloid malignancies who are getting myelosuppressive anti-cancer drugs.

The regulatory agency conducted a pre-approval inspection of the plant in mid-September. 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The Biocon/Mylan partnership has commercialized three of its co-developed biosimilars in U.S., Canadian, European, and Australian markets.

“This approval will help us better meet global patient needs for Fulphila,” Dr. Christiane Hamacher, Biocon Biologic’s chief executive, said in a statement. “Continued penetration of biosimilars will enable higher cost savings for the U.S. healthcare system leading to expansion of patient access to high-quality, affordable biologics.”

With the regulatory agency approval of Biocon’s additional facility, it and Mylan will be in a position to meet increasing patient demand for the drug in the U.S. where introduction of the biosim has expanded the overall market, the company said. Fulphila has already been approved in the European Union, Australia and Canada.

Fulphila, which is a knockoff of Amgen’s Neulasta, has already captured more than 15% of the prefilled syringe market, and Mylan has said it is using a patient-focused call center, reimbursement support and copay assistance to drive their market share higher.

Suggested Articles

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.

Despite the coronavirus posing a challenge to pharma's supply chain, generics makers could make out well in the ongoing pandemic, one analyst says.

After nearly five years Xellia Pharmaceuticals has started commercial production at former Boehringer Ingelheim sterile injectables plant.